Evidence map›Paper›PMID 37477653›Full record

ArticleCancer immunology, immunotherapy : CII2023

Good manufacturing practice production of CD34

P K J D de Jonge, P M M van Hauten, L D Janssen, A L de Goede, M M Berrien-Elliott, J M R van der Meer, C M Mousset, M W H Roeven, M Foster, N Blijlevens and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Natural killer cell-based immunotherapy for cancer.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Review
  7. Good manufacturing practice production of an off-the-shelf CD34Cellular and molecular life sciences : CMLS · 2025
    Article
  8. Feeder-cell-free system forFrontiers in immunology · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

P K J D de Jonge *Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
P M M van Hauten *Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
L D JanssenDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
A L de GoedeDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
M M Berrien-ElliottDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, USA.
J M R van der MeerDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
C M MoussetDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
M W H RoevenDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
M FosterDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, USA.
N BlijlevensDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
W HoboDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
T A FehnigerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, USA.
J H JansenDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
N P M SchaapDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
H DolstraDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. harry.dolstra@radboudumc.nl.
Radboud University Nijmegen · NLRadboud University Medical Center · NLWashington University in St. Louis · US

Funding

Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPYR01CA205239 · NCI · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2017 to 2020
$2.4M
NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA205239NIH HHS R01CA205239
6 · The paper itself

Abstract

Allogeneic natural killer (NK) cell-based immunotherapy is a promising, well-tolerated adjuvant therapeutic approach for acute myeloid leukemia (AML). For reproducible NK cell immunotherapy, a homogenous, pure and scalable NK cell product is preferred. Therefore, we developed a good manufacturing practice (GMP)-compliant, cytokine-based ex vivo manufacturing process for generating NK cells from CD34

Indexed as

Immunotherapy, AdoptiveLeukemia, Myeloid, AcuteAntigens, CD34Hematopoietic Stem CellsHumansKiller Cells, NaturalAntigens, CD34Adoptive transferCell manufacturingGood manufacturing practice (GMP)ImmunotherapyNatural killer (NK) cells

Identifiers

PMID37477653
PMCPMC10491545
OpenAlexW4384925344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.